Press release
Investigation announced for Investors in Morphic Holding, Inc. (NASDAQ: MORF) over potential Wrongdoing
An investigation on behalf of investors in Morphic Holding, Inc. (NASDAQ: MORF) shares over potential wrongdoing.
Investors who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Morphic Holding, Inc officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Waltham, MA based Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Morphic Holding, Inc. reported that its annual Total Revenue rose from $19.79 million in 2021 to $70.8 million in 2022 and that its Net Loss declined from $95.54 million in 2021 to $59.04 million in 2022.
On September 22, 2023, the Company released abstract data from its EMERALD-1 Phase 2a trial for its drug candidate, MORF-057. Following this news, the price of the Company's stock dropped.
Shares of Morphic Holding, Inc. (NASDAQ: MORF) declined from $63.08 per share on June 12, 2023, to as low as $19.96 per share on Octboer 25, 2023.
Those who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Morphic Holding, Inc. (NASDAQ: MORF) over potential Wrongdoing here
News-ID: 3489797 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Primo Brands Corporati …
An investor, who purchased shares of Primo Brands Corporation (NYSE: PRMB), filed a lawsuit over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Primo Water (formerly NYSE: PRMW) between June 17, 2024 through November 8, 2024, and/or purchased a significant amount of shares Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 through November 6,…
Lawsuit Alert: Investors who lost a substantial amount with Telix Pharmaceutical …
An investor, who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Telix Pharmaceuticals Limited in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Telix Pharmaceuticals Limited (NASDAQ: TLX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 9, 2026. NASDAQ: TLX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in shares of Savara Inc. (NASDAQ …
An investigation was announced for long-term investors in shares of Savara Inc. (NASDAQ: SVRA) concerning potential breaches of fiduciary duties by certain directors of Savara Inc.
Investors who are current long term investors in Savara Inc. (NASDAQ: SVRA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SVRA stocks…
Lawsuit filed for Investors who lost money with shares of Inspire Medical System …
An investor, who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP), filed a lawsuit over alleged violations of Federal Securities Laws by Inspire Medical Systems, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Inspire Medical Systems, Inc. (NYSE: INSP) have certain options and for certain investors are short and strict deadlines running. Deadline: January 5, 2026. NYSE: INSP investors should contact the Shareholders…
More Releases for Morphic
Primary Sclerosing Cholangitis Pipeline Outlook Report 2025: Emerging Therapies …
DelveInsight's "Primary Sclerosing Cholangitis Pipeline Insights 2025" report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the Primary Sclerosing Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Sclerosing Cholangitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead…
Inflammatory Bowel Disease Market Positioned for Accelerated Development Through …
The Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
DelveInsight's "Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding…
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion - …
Eli Lilly and Company (LLY) on July 8, 2024, entered a definitive merger agreement to acquire Morphic Holding, Inc. (MORF) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.
Eli Lilly and Company (NYSE: LLY [https://www.insidearbitrage.com/symbol-metrics/LLY/?utm_source=ABNewswire&utm_medium=PaidPr&utm_campaign=Lilly-Morphic]), a global leader in the pharmaceutical industry, on July 8, 2024, announced the completion of a definitive agreement to acquire Morphic Therapeutic, Inc. (NASDAQ:…
Primary Sclerosing Cholangitis Pipeline Analysis (2023) Covering Clinical Trials …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 14+ key pharma and biotech companies are working on 14+ pipeline drugs in the Primary Sclerosing Cholangitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Primary Sclerosing Cholangitis Pipeline Insight,…
Investigation announced for Investors who lost money with shares of Morphic Hold …
An investigation on behalf of investors of Morphic Holding, Inc. (NASDAQ: MORF) shares over potential securities laws violations by Morphic Holding, Inc. and certain of its directors and officers in connection with certain financial statements was announced.
Investors who purchased shares of Morphic Holding, Inc. (NASDAQ: MORF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on…
Global Integrin Beta 1 Market Growth, Trends and Forecast 2021 to 2027 - Avipero …
Global Integrin Beta 1 Market Research Report 2021-2027 is the latest research study published by Market Research Place that aims to gather, record, and analyze the data for the concerns linked to the marketing of goods and services and thereby serve the global industry with an excellent market research report. The report identifies industry trends, determines brand awareness and influence, provides industry insights, and offers competitive intelligence. This report carries…
